Lim Bryant David 4
4 · Prelude Therapeutics Inc · Filed Dec 20, 2024
Insider Transaction Report
Form 4
Lim Bryant David
CLO, CFO, Corp Sec.
Transactions
- Purchase
Common Stock
2024-12-19$0.91/sh+25,000$22,638→ 27,400 total
Footnotes (1)
- [F1]1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.87 to $0.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.